Real-world diagnostic landscape and incidence of pulmonary hypertension in adult congenital heart disease patients using administrative claims data in Japan

References

• Liu A, Diller GP, Moons P, et al. Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults. Nat Rev Cardiol. 2023;20(2):126–137. doi: 10.1038/s41569-022-00749-y.
   PubMed Web of Science ®Google Scholar
• Chiu SN, Lu CW, Lin MT, et al. Pulmonary hypertension in adult congenital heart disease in asia: a distinctive feature of complex congenital heart disease. J Am Heart Assoc. 2022;11(7):e022596. doi: 10.1161/jaha.121.022596.
   PubMed Web of Science ®Google Scholar
• Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol. 2011;58(5):538–546. doi: 10.1016/j.jacc.2011.03.033.
   PubMed Web of Science ®Google Scholar
• van Riel AC, Schuuring MJ, van Hessen ID, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014;174(2):299–305. doi: 10.1016/j.ijcard.2014.04.072.
   PubMed Web of Science ®Google Scholar
• Yao A, Inuzuka R, Mizuno A, et al. Status of adult outpatients with congenital heart disease in Japan: the Japanese network of cardiovascular departments for adult congenital heart disease registry. J Cardiol. 2022;80(6):525–531. doi: 10.1016/j.jjcc.2022.07.019.
   PubMed Web of Science ®Google Scholar
• Schwartz SS, Madsen N, Laursen HB, et al. Incidence and mortality of adults with pulmonary hypertension and congenital heart disease. Am J Cardiol. 2018;121(12):1610–1616. doi: 10.1016/j.amjcard.2018.02.051.
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Lau EM. Pulmonary hypertension definition, classification, and epidemiology in asia. JACC Asia. 2022;2(5):538–546. doi: 10.1016/j.jacasi.2022.04.008.
   PubMedGoogle Scholar
• Arvanitaki A, Giannakoulas G, Baumgartner H, et al. Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart. 2020;106(21):1638–1645. doi: 10.1136/heartjnl-2020-316665.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. doi: 10.1093/eurheartj/ehv317.
   PubMed Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. doi: 10.1093/eurheartj/ehac237.
   PubMed Web of Science ®Google Scholar
• Joint Research Group Societies. Guidelines for management of congential heart diseases in adults (JCS 2017), March 23, 2018. In Japanese.
   Google Scholar
• Joint Research Group Societies. Guidelines for treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017), Published March 23, 2018. Corrigendum published December 23, 2021. In Japanese.
   Google Scholar
• Laurent T, Simeone J, Kuwatsuru R, et al. Context and considerations for use of two Japanese real-world databases in Japan: medical data vision and Japanese medical data center. Drugs Real World Outcomes. 2022;9(2):175–187. doi: 10.1007/s40801-022-00296-5.
   PubMedGoogle Scholar
• Yasunaga H. Real world data in Japan: chapter II the diagnosis procedure combination database. ACE. 2019;1(3):76–79. doi: 10.37737/ace.1.3_76.
   Google Scholar
• Kaemmerer H, Gorenflo M, Huscher D, et al. Pulmonary hypertension in adults with congenital heart disease: real-world data from the international COMPERA-CHD registry. J Clin Med. 2020;9(5):1456. doi: 10.3390/jcm9051456.
   PubMed Web of Science ®Google Scholar
• Nitta M, Ochiai R, Nakano S, et al. Characteristics of patients with adult congenital heart disease treated by non-specialized doctors: the potential loss of follow-up. J Cardiol. 2021;77(1):17–22. doi: 10.1016/j.jjcc.2020.06.018.
   PubMed Web of Science ®Google Scholar
• Pascall E, Tulloh RM. Pulmonary hypertension in congenital heart disease. Future Cardiol. 2018;14(4):343–353. doi: 10.2217/fca-2017-0065.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Oyanagi G, Obara T, et al. Validity of congenital malformation diagnoses in healthcare claims from a university hospital in Japan. Pharmacoepidemiol Drug Saf. 2021;30(7):975–978. doi: 10.1002/pds.5244.
   PubMed Web of Science ®Google Scholar
• Stout KK, Broberg CS, Book WM, et al. Chronic heart failure in congenital heart disease: a scientific statement from the American heart association. Circulation. 2016;133(8):770–801. doi: 10.1161/cir.0000000000000352.
   PubMed Web of Science ®Google Scholar
• Usuku H, Yamamoto E, Oike F, et al. Current awareness and status of transthoracic echocardiography in Kumamoto prefecture – a report of the Kumamoto cardiovascular echocardiography standardization project. Circ Rep. 2020;2(6):297–305. doi: 10.1253/circrep.CR-20-0028.
   PubMedGoogle Scholar
• Joint Research Group Societies. Guidelines for treatment of acute heart failure (JCS 2011), September 20, 2013. In Japanese.
   Google Scholar
• Joint Research Group Societies. Guidelines for treatment of chronic heart failure (JCS 2010), September 13, 2013. In Japanese.
   Google Scholar
• Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val-HeFT) data. Clin Chem. 2006;52(8):1528–1538. doi: 10.1373/clinchem.2006.069575.
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Sakai H, Nishiyama K, et al. Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circ J. 2007;71(12):1873–1878. doi: 10.1253/circj.71.1873.
   PubMed Web of Science ®Google Scholar
• Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109–D116. doi: 10.1016/j.jacc.2013.10.036.
   PubMed Web of Science ®Google Scholar
• Nitta M, Shimizu S, Kaneko M, et al. Outcomes of women with congenital heart disease admitted to acute-care hospitals for delivery in Japan: a retrospective cohort study using nationwide Japanese diagnosis procedure combination database. BMC Cardiovasc Disord. 2021;21(1):409. doi: 10.1186/s12872-021-02222-z.
   PubMed Web of Science ®Google Scholar
• Emmons-Bell S, Johnson C, Boon-Dooley A, et al. Prevalence, incidence, and survival of pulmonary arterial hypertension: a systematic review for the global burden of disease 2020 study. Pulm Circ. 2022;12(1):e12020. doi: 10.1002/pul2.12020.
   PubMed Web of Science ®Google Scholar
• Rubio-Rivas M, Homs NA, Cuartero D, et al. The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: systematic review and meta-analysis. Autoimmun Rev. 2021;20(1):102713. doi: 10.1016/j.autrev.2020.102713.
   PubMed Web of Science ®Google Scholar
• Jolley M, Colan SD, Rhodes J, et al. Fontan physiology revisited. Anesth Analg. 2015;121(1):172–182. doi: 10.1213/ane.0000000000000717.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41. doi: 10.1016/j.jacc.2013.10.029.
   PubMed Web of Science ®Google Scholar
• Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (treatment with endothelin receptor antagonist in Fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study. Circulation. 2014;130(23):2021–2030. doi: 10.1161/circulationaha.113.008441.
   PubMed Web of Science ®Google Scholar
• Mori H, Park IS, Yamagishi H, et al. Sildenafil reduces pulmonary vascular resistance in single ventricular physiology. Int J Cardiol. 2016;221:122–127. doi: 10.1016/j.ijcard.2016.06.322.
   PubMed Web of Science ®Google Scholar
• Van De Bruaene A, La Gerche A, Claessen G, et al. Sildenafil improves exercise hemodynamics in Fontan patients. Circ Cardiovasc Imaging. 2014;7(2):265–273. doi: 10.1161/circimaging.113.001243.
   PubMed Web of Science ®Google Scholar
• Toma M, Miceli R, Bonsante E, et al. Left heart disease phenotype in elderly patients with pulmonary arterial hypertension: insights from the italian PATRIARCA registry. J Clin Med. 2022;11(23):7136. doi: 10.3390/jcm11237136.
   PubMed Web of Science ®Google Scholar
• de Amorim Corrêa R, de Oliveira FB, Barbosa MM, et al. Left ventricular function in patients with pulmonary arterial hypertension: the role of two-dimensional speckle tracking strain. Echocardiography. 2016;33(9):1326–1334. doi: 10.1111/echo.13267.
   PubMed Web of Science ®Google Scholar